Wedbush Equities Analysts Cut Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at Wedbush reduced their Q2 2025 EPS estimates for TScan Therapeutics in a research report issued on Tuesday, May 6th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.26) per share for the quarter, down from their previous forecast of ($0.25). Wedbush has a "Outperform" rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.91) EPS.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a report on Tuesday, April 8th. Morgan Stanley reissued an "overweight" rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. Barclays lowered their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright lowered their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $8.50.

TScan Therapeutics Stock Down 5.0%

TCRX stock traded down $0.07 during midday trading on Friday, reaching $1.26. The company had a trading volume of 119,384 shares, compared to its average volume of 361,717. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $71.49 million, a P/E ratio of -1.19 and a beta of 1.06. The company has a 50 day moving average of $1.47 and a two-hundred day moving average of $2.66.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of TScan Therapeutics by 341.1% during the third quarter. Barclays PLC now owns 58,067 shares of the company's stock worth $289,000 after buying an additional 44,903 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of TScan Therapeutics by 94.4% during the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company's stock worth $158,000 after buying an additional 15,441 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after buying an additional 4,852 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $61,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $32,000. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.